IBio's stock soars, but Novavax and Inovio stocks fall amid news on other COVID-19 vaccine candidates

Shares of companies with COVID-19 vaccine candidates were mixed in volatile trading Monday, after the promising results from trials of vaccine candidates from Pfizer Inc. PFE, -0.61% and BioNTech SE BNTX, -1.22% and AstraZeneca PLC AZN, -1.00% AZN, -0.53%. Shares of iBio Inc. IBIO, -7.61%, which is working with Beijing CC-Pharming Ltd. on a plant-based vaccine to treat the coronavirus, soared 43% in morning trading on volume of 45.5 million shares, which is already nearly double the full-day average. Inovio Pharmaceuticals Inc. INO, -4.86%, which announced last month that the Department of Defense will pay $71 million to fund the manufacturing of a device used to administer Inovio vaccines, saw its stock drop 7.9%. Among other companies with vaccine candidates, shares of Moderna Inc. MRNA, -4.60% sank 12% in active trading after a J.P. Morgan downgrade on valuation concerns, Novavax Inc. NVAX, -4.96% shed 5%, Vaxart Inc. VXRT, -5.94% gained 1.9%. Meanwhile, shares of AstraZeneca fell 2.9%, Pfizer gained 1.8% and BioNTech advanced 4.9%. The S&P 500 SPX, -1.73% was up less than 0.1% in morning trading.